A Prospective Observational Registry to describe the disease course and outcomes of Idiopathic Pulmonary Fibrosis patients in a real-world clinical setting

Study Objective:

• Primary objective:

• To describe the disease course and outcomes in IPF patients.

• Secondary objectives:

• To describe the IPF-related therapies and concomitant therapies at baseline and throughout the course of the registry
• To describe Quality of Life evolution overtime
• To assess safety of treatments used to treat IPF
• To describe use of health care resources throughout the course of the registry

NOTE: As an observational registry, this registry will not change the patient /doctor relationship, nor influence the Doctor’s drug prescription or therapeutic management of the patient. The study will consist in data collection of routine clinical visits

Participation conditions

Inclusion criteria:

• Patients >18 years of age
• IPF diagnosis “definite” or “probable” (definitions according to 2011 ATS/ERS guidelines), confirmed by a multidisciplinary team (minimum of pulmonologist, radiologist, pathologist, all with expertise in IPF).
• Patients who agreed to participate in the registry and have completed and signed the Informed Consent Form

Exclusion criteria:

• Patients incapable of giving informed consent
• Participation in a clinical study at the time of inclusion in the registry and whose protocol does not allow participation in another study
   

Centre Hospitalier de Luxembourg (CHL)